|
|
Syros Pharmaceuticals Inc (NASDAQ: SYRS) |
|
*Market share is calculated based on total revenue.
Publicly Traded Peers of Syros Pharmaceuticals Inc
Verona Pharma Plc
Share Performance
+2.30%
Over The Past 5 Days
|
Verona Pharma Plc
Profile
Verona Pharma Plc is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for respiratory diseases. Their business model revolves around discovering and advancing new drug candidates, conducting clinical trials, and ultimately bringing these potential treatments to market. By leveraging their expertise in respiratory medicine, they aim to address unmet medical needs and improve the lives of patients suffering from respiratory conditions.
More about Verona Pharma Plc's Market Share
|
Phathom Pharmaceuticals Inc
Share Performance
+146.34%
30 Days
|
Phathom Pharmaceuticals Inc
Profile
Phathom Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing treatments for gastrointestinal diseases. Their business model involves advancing their pipeline of drug candidates through research and development, and seeking regulatory approval for commercialization. By strategically targeting unmet medical needs in the gastrointestinal space, Phathom Pharmaceuticals aims to provide innovative solutions to improve patient outcomes.
More about Phathom Pharmaceuticals Inc 's Market Share
|
G1 Therapeutics Inc
Share Performance
+0.56%
30 Days
|
G1 Therapeutics Inc
Profile
G1 Therapeutics Inc is a biopharmaceutical company that operates under a research and development business model. They focus on discovering, developing, and commercializing novel therapies to address unmet needs in cancer treatment, with a strong emphasis on targeting specific cellular processes. Their business model involves conducting preclinical and clinical trials, obtaining regulatory approvals, and collaborating with strategic partners to bring their innovative drugs to market.
More about G1 Therapeutics Inc 's Market Share
|
Blueprint Medicines Corporation
Share Performance
+44.50%
This Quarter
|
Blueprint Medicines Corporation
Profile
The business model of Blueprint Medicines Corporation revolves around the development and commercialization of precision therapies for patients with genomically defined cancers and rare diseases. They actively pursue a strategy of genomically targeted drug discovery and development, utilizing advanced technologies and clinical expertise to bring potentially life-changing treatments to market. The company focuses on creating value through strategic collaborations, licensing agreements, and the commercialization of their innovative therapies.
More about Blueprint Medicines Corporation's Market Share
|
Mirati Therapeutics Inc
Share Performance
+22.52%
One Year
|
Mirati Therapeutics Inc
Profile
Mirati Therapeutics Inc is a biotechnology company that focuses on the research, discovery, and development of precision oncology treatments for patients with cancer. Their business model involves leveraging their proprietary drug discovery platform to identify and develop targeted therapies, and collaborating with partners for the commercialization of their products.
More about Mirati Therapeutics Inc 's Market Share
|
Zymeworks Inc
Share Performance
-1.89%
This Quarter
|
Zymeworks Inc
Profile
Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.
More about Zymeworks Inc 's Market Share
|
Agios Pharmaceuticals Inc
Share Performance
+8.07%
This Year
|
Agios Pharmaceuticals Inc
Profile
Agios Pharmaceuticals Inc is a biopharmaceutical company that focuses on researching and developing innovative therapies for treating genetic diseases and cancer.
More about Agios Pharmaceuticals Inc 's Market Share
|
Lipella Pharmaceuticals Inc
Share Performance
-37.50%
Over The Past 5 Days
|
Lipella Pharmaceuticals Inc
Profile
: { message: That model is currently overloaded with other requests. You can retry your request, or contact us through our help center at help.openai.com if the error persists. (Pleas
More about Lipella Pharmaceuticals Inc 's Market Share
|
Glycomimetics Inc
Share Performance
-38.50%
This Year
|
Glycomimetics Inc
Profile
Glycomimetics Inc is a biopharmaceutical company that utilizes its expertise in carbohydrate chemistry to develop novel drug candidates. Their business model involves researching and developing proprietary glycomimetic compounds that can target specific disease pathways. They then collaborate with pharmaceutical partners to further develop and commercialize these potential therapeutics.
More about Glycomimetics Inc 's Market Share
|
Mersana Therapeutics inc
Share Performance
-82.82%
One Year
|
Mersana Therapeutics inc
Profile
Mersana Therapeutics Inc's business model focuses on developing and commercializing novel antibody-drug conjugates (ADCs) for the treatment of cancer.
More about Mersana Therapeutics inc 's Market Share
|
Lantern Pharma Inc
Share Performance
-3.64%
This Year
|
Lantern Pharma Inc
Profile
Lantern Pharma Inc's business model focuses on leveraging artificial intelligence and machine learning to identify and repurpose existing drugs for the treatment of various diseases.
More about Lantern Pharma Inc 's Market Share
|
Puretech Health Plc
Share Performance
-8.21%
30 Days
|
Puretech Health Plc
Profile
Puretech Health Plc is a biotechnology company that operates a unique business model focusing on innovation and entrepreneurship. They identify and validate disruptive technologies and build and invest in companies around those technologies, with a focus on identifying unmet medical needs. By developing a diversified portfolio of cutting-edge healthcare companies, Puretech aims to deliver breakthrough therapies to improve patient outcomes.
More about Puretech Health Plc's Market Share
|
Milestone Pharmaceuticals Inc
Share Performance
+2.42%
Over The Past 5 Days
|
Milestone Pharmaceuticals Inc
Profile
Milestone Pharmaceuticals Inc. is a pharmaceutical company that focuses on developing and commercializing innovative therapies for cardiovascular diseases. Their business model revolves around identifying unmet medical needs in the cardiovascular space and leveraging their expertise in drug development to create novel treatments. By conducting rigorous research, clinical trials, and collaborations, Milestone Pharmaceuticals aims to bring effective and safe medications to market, positively impacting patients' lives.
More about Milestone Pharmaceuticals Inc 's Market Share
|
Precigen Inc
Share Performance
+34.26%
This Year
|
Precigen Inc
Profile
Precigen Inc is a biotechnology company that focuses on the development and commercialization of innovative genetic therapies. Their business model revolves around leveraging their proprietary technologies and expertise in gene editing and synthetic biology to create transformative medical solutions. With a strong emphasis on research and development, Precigen aims to bring cutting-edge genetic therapies to market and address critical unmet medical needs.
More about Precigen Inc 's Market Share
|
Day One Biopharmaceuticals Inc
Share Performance
-23.21%
This Quarter
|
Day One Biopharmaceuticals Inc
Profile
Day One Biopharmaceuticals Inc operates with a business model focused on developing targeted therapies for patients with rare genetic diseases and cancer. They aim to leverage their expertise in precision medicine and drug discovery to create innovative treatments that address unmet medical needs. Their approach involves identifying genetic mutations and developing therapies tailored specifically to target these mutations and improve patient outcomes.
More about Day One Biopharmaceuticals Inc 's Market Share
|
Shattuck Labs Inc
Share Performance
-20.92%
This Year
|
Shattuck Labs Inc
Profile
Shattuck Labs Inc operates through a platform-based business model, focusing on the development of biotechnology products and solutions. By utilizing its proprietary technology and expertise, the company aims to create innovative therapies targeting various diseases and disorders, ultimately improving patient outcomes. Shattuck Labs Inc collaborates with strategic partners and stakeholders to advance its pipeline, aiming to commercialize its novel treatments and drive growth in the biotech industry.
More about Shattuck Labs Inc 's Market Share
|
Jazz Pharmaceuticals Plc
Share Performance
-13.13%
This Year
|
Jazz Pharmaceuticals Plc
Profile
Jazz Pharmaceuticals Plc is a biopharmaceutical company focused on developing and commercializing innovative therapies for a range of medical conditions. Their business model revolves around conducting extensive research and development to identify novel molecules and compounds that can address unmet medical needs. By leveraging strategic partnerships, acquisitions, and licensing agreements, they aim to bring these therapies to market and provide valuable treatment options to patients worldwide.
More about Jazz Pharmaceuticals Plc's Market Share
|
Alnylam Pharmaceuticals Inc
Share Performance
+32.57%
This Year
|
Alnylam Pharmaceuticals Inc
Profile
Alnylam Pharmaceuticals Inc's business model focuses on developing and commercializing RNA interference (RNAi) therapeutics.
More about Alnylam Pharmaceuticals Inc 's Market Share
|
Biomarin Pharmaceutical Inc
Share Performance
-22.80%
This Quarter
|
Biomarin Pharmaceutical Inc
Profile
Biomarin Pharmaceutical Inc operates as a biotechnology company, specializing in the development and commercialization of innovative therapies for rare genetic diseases. Their business model revolves around conducting extensive research and development to identify and address unmet medical needs, manufacturing and marketing their approved products, and collaborating with strategic partners to maximize the reach and impact of their therapies worldwide. By focusing on rare diseases, Biomarin leverages their expertise to provide targeted and innovative treatments, ultimately improving the lives of patients in need.
More about Biomarin Pharmaceutical Inc's Market Share
|
Vertex Pharmaceuticals Inc
Share Performance
+1.58%
30 Days
|
Vertex Pharmaceuticals Inc
Profile
Vertex Pharmaceuticals Incs business model centers on the research and development of innovative therapies, primarily targeting cystic fibrosis and other serious diseases. They emphasize collaboration with organizations, strategic partnerships, and robust investment in R&D to deliver transformative treatments to patients and enhance their quality of life.
More about Vertex Pharmaceuticals Inc's Market Share
|
Deciphera Pharmaceuticals Inc
Share Performance
+0.08%
Over The Past 5 Days
|
Deciphera Pharmaceuticals Inc
Profile
Deciphera Pharmaceuticals Inc's business model revolves around the research, development, and commercialization of precision medicines for the treatment of cancer and other serious diseases.
More about Deciphera Pharmaceuticals Inc 's Market Share
|
Xencor Inc
Share Performance
-7.07%
Over The Past 5 Days
|
Xencor Inc
Profile
Xencor Inc is a biotechnology company that primarily focuses on the development of therapeutic antibodies. Their business model revolves around utilizing their proprietary XmAb? technology to engineer antibodies with enhanced properties for the treatment of various diseases. They collaborate with pharmaceutical companies to develop and commercialize these antibody therapeutics, generating revenue through upfront payments, milestone payments, and royalties.
More about Xencor Inc's Market Share
|
Zai Lab Limited
Share Performance
-1.54%
This Quarter
|
Zai Lab Limited
Profile
Zai Lab Limited operates as a biopharmaceutical company primarily in China. The company seeks to discover, develop, and commercialize innovative medicines to address unmet medical needs in the country. Zai Lab focuses on licensing and acquiring clinical stage or late-stage development drugs, and then progressing them through regulatory approval and commercial launch.
More about Zai Lab Limited's Market Share
|
Intercept Pharmaceuticals inc
Share Performance
+82.87%
This Quarter
|
Intercept Pharmaceuticals inc
Profile
Intercept Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development and commercialization of novel therapeutics in the field of chronic liver diseases. Their business model revolves around identifying and targeting specific liver diseases with high unmet medical needs, conducting extensive research and clinical trials to develop effective therapies, and then commercializing these drugs globally to generate sustainable revenue streams. By addressing liver diseases with innovative treatments, Intercept aims to improve patient outcomes and establish a profitable position in the pharmaceutical industry.
More about Intercept Pharmaceuticals inc 's Market Share
|
Supernus Pharmaceuticals inc
Share Performance
-11.39%
This Year
|
Supernus Pharmaceuticals inc
Profile
Supernus Pharmaceuticals Inc operates under a unique business model focused on the development and commercialization of innovative treatments for central nervous system (CNS) diseases. The company combines in-house expertise with strategic partnerships to efficiently advance and bring their products to market. By prioritizing CNS disorders and utilizing a collaborative approach, Supernus Pharmaceuticals strives to address unmet medical needs and improve the lives of patients.
More about Supernus Pharmaceuticals inc 's Market Share
|
Nurix Therapeutics Inc
Share Performance
-46.06%
One Year
|
Nurix Therapeutics Inc
Profile
Nurix Therapeutics Inc's business model involves developing targeted protein degradation therapies to treat diseases by modulating the body's cellular protein levels.
More about Nurix Therapeutics Inc 's Market Share
|
Cytodyn inc
Share Performance
+121.43%
One Year
|
Cytodyn inc
Profile
Cytodyn Inc is a biotechnology company that focuses on the development and commercialization of innovative treatments for a range of diseases, including cancer and viral infections. The company primarily generates revenue through the licensing and sale of its therapeutics to medical institutions and pharmaceutical companies. Cytodyn's business model revolves around the research and development of novel drugs, conducting clinical trials, and forming strategic partnerships to bring their innovative treatments to market.
More about Cytodyn inc 's Market Share
|
Madrigal Pharmaceuticals Inc
Share Performance
-16.36%
This Quarter
|
Madrigal Pharmaceuticals Inc
Profile
Madrigal Pharmaceuticals Inc's business model is focused on developing and commercializing innovative therapeutic solutions for liver diseases, with a particular emphasis on non-alcoholic steatohepatitis (NASH) and other metabolic diseases. They aim to provide effective treatments to address unmet medical needs and improve patient outcomes in these areas.
More about Madrigal Pharmaceuticals Inc 's Market Share
|
89bio Inc
Share Performance
+4.46%
30 Days
|
89bio Inc
Profile
89bio Inc operates as a biopharmaceutical company focused on developing and commercializing transformative therapies for liver and cardio-metabolic diseases. The company's business model revolves around identifying and developing potential drug candidates through its unique platform, with the aim of meeting the unmet medical needs of patients. By leveraging its expertise and scientific advancements, 89bio Inc strives to bring innovative treatments to market, improving the lives of individuals suffering from these conditions.
More about 89bio Inc 's Market Share
|
Allakos Inc
Share Performance
+1.89%
30 Days
|
Allakos Inc
Profile
Allakos Inc's business model revolves around developing and commercializing innovative therapeutic antibodies to treat allergic and inflammatory diseases.
More about Allakos Inc 's Market Share
|
Iveric Bio Inc
Share Performance
+252.92%
One Year
|
Iveric Bio Inc
Profile
Iveric Bio Inc's business model involves the development and commercialization of innovative gene therapy treatments for the treatment of retinal diseases.
More about Iveric Bio Inc 's Market Share
|
Kinnate Biopharma Inc
Share Performance
+6.43%
This Year
|
Kinnate Biopharma Inc
Profile
Kinnate Biopharma Inc is a company that focuses on developing targeted therapies for genetically-defined cancers.
More about Kinnate Biopharma Inc 's Market Share
|
Actinium Pharmaceuticals Inc
Share Performance
-3.23%
This Quarter
|
Actinium Pharmaceuticals Inc
Profile
Actinium Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of targeted therapies for the treatment of various cancers.
More about Actinium Pharmaceuticals Inc's Market Share
|
Oramed Pharmaceuticals Inc
Share Performance
-8.58%
This Quarter
|
Oramed Pharmaceuticals Inc
Profile
Oramed Pharmaceuticals Inc. is a biopharmaceutical company with a business model focused on developing innovative oral drug delivery solutions.
More about Oramed Pharmaceuticals Inc's Market Share
|
Tg Therapeutics Inc
Share Performance
+5.20%
30 Days
|
Tg Therapeutics Inc
Profile
TG Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing innovative treatments for patients with hematological malignancies and autoimmune diseases.
More about Tg Therapeutics Inc 's Market Share
|
Reata Pharmaceuticals Inc
Share Performance
+2.14%
30 Days
|
Reata Pharmaceuticals Inc
Profile
Reata Pharmaceuticals Inc is a biopharmaceutical company focused on developing innovative therapeutics for serious and life-threatening diseases. Their business model centers around the discovery, development, and commercialization of novel drugs based on their proprietary technology platform. Reata Pharmaceuticals aims to bring transformative treatments to patients, partnering with other organizations and leveraging their expertise to deliver value to stakeholders.
More about Reata Pharmaceuticals Inc 's Market Share
|
Wave Life Sciences Ltd
Share Performance
+25.14%
One Year
|
Wave Life Sciences Ltd
Profile
Wave Life Sciences Ltd is a biotechnology company focused on developing and commercializing nucleic acid therapies for rare genetic diseases. Their business model revolves around utilizing their proprietary chemistry platform to design and create custom-built, targeted medicines that can potentially address a wide range of genetic disorders. They aim to bring these therapies through preclinical and clinical development stages and ultimately deliver innovative treatments to patients in need.
More about Wave Life Sciences Ltd 's Market Share
|
Janux Therapeutics Inc
Share Performance
-21.18%
This Quarter
|
Janux Therapeutics Inc
Profile
Janux Therapeutics Inc is a biotechnology company that focuses on developing and commercializing innovative cancer treatments. Their business model revolves around leveraging their expertise in immunotherapies and bispecific antibody platforms to create novel therapies that target tumor cells and activate the patient's immune system. By partnering with pharmaceutical companies and conducting clinical trials, they aim to bring effective and personalized cancer treatments to market.
More about Janux Therapeutics Inc 's Market Share
|
Mira Pharmaceuticals Inc
Share Performance
+70.13%
One Year
|
Mira Pharmaceuticals Inc
Profile
Mira Pharmaceuticals Inc's business model is focused on the development and sale of pharmaceutical products, with a particular emphasis on research and innovation in the healthcare industry.
More about Mira Pharmaceuticals Inc 's Market Share
|
Innovation Pharmaceuticals Inc
Share Performance
0.00%
One Year
|
Innovation Pharmaceuticals Inc
Profile
Innovation Pharmaceuticals Inc operates under a business model focused on pharmaceutical research and development. They strive to innovate and discover novel drug candidates to address unmet medical needs. Through collaborations, partnerships, and internal capabilities, they aim to bring potential therapies through clinical trials and eventually to market.
More about Innovation Pharmaceuticals Inc 's Market Share
|
Inhibitor Therapeutics Inc
Share Performance
0.00%
Over The Past 5 Days
|
Inhibitor Therapeutics Inc
Profile
Inhibitor Therapeutics Inc's business model focuses on developing and commercializing innovative inhibitors for targeted therapies.
More about Inhibitor Therapeutics Inc 's Market Share
|
Regenerx Biopharmaceuticals inc
Share Performance
0.00%
Over The Past 5 Days
|
Regenerx Biopharmaceuticals inc
Profile
Regenerx Biopharmaceuticals Inc operates with a business model based on developing and commercializing innovative therapeutic products. They focus on utilizing regenerative medicine to address unmet medical needs in various therapeutic areas, including ophthalmology and dermatology. The company aims to identify promising drug candidates, conduct clinical trials, and ultimately bring their products to market to improve patients' lives.
More about Regenerx Biopharmaceuticals inc 's Market Share
|
Aravive Inc
Share Performance
-97.76%
One Year
|
Aravive Inc
Profile
Aravive Inc operates on a business model that focuses on developing and commercializing innovative therapies to treat life-threatening diseases by targeting key signaling pathways.
More about Aravive Inc 's Market Share
|
Tyme Technologies Inc.
Share Performance
+22.47%
This Quarter
|
Tyme Technologies Inc.
Profile
Tyme Technologies Inc. is a biotechnology company that operates through the development and commercialization of pharmaceutical products. Their business model focuses on the research, development, and sale of proprietary cancer therapy drug candidates. By leveraging innovative technology and strategic partnerships, Tyme aims to bring novel treatment options to the market, improving patient outcomes and addressing unmet medical needs in the oncology field.
More about Tyme Technologies Inc.'s Market Share
|
Nucana Plc
Share Performance
-96.63%
One Year
|
Nucana Plc
Profile
Nucana Plc is a pharmaceutical company that focuses on developing novel treatments for cancer and other diseases.
More about Nucana Plc's Market Share
|
Tonix Pharmaceuticals Holding Corp
Share Performance
+3.06%
This Year
|
Tonix Pharmaceuticals Holding Corp
Profile
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing and commercializing innovative therapies for psychiatric and neurological conditions. Their business model revolves around identifying potential drug candidates, conducting preclinical and clinical trials to evaluate their efficacy and safety, and ultimately obtaining regulatory approval for their products to bring them to market. Through strategic partnerships and collaborations, they aim to commercialize and distribute their therapies to provide much-needed treatment options for patients.
More about Tonix Pharmaceuticals Holding Corp 's Market Share
|
Effector Therapeutics Inc
Share Performance
-50.00%
This Year
|
Effector Therapeutics Inc
Profile
Effector Therapeutics Inc is a biotech company focused on developing and commercializing effective cancer treatments.
More about Effector Therapeutics Inc 's Market Share
|
Affimed N v
Share Performance
0.00%
This Quarter
|
Affimed N v
Profile
Affimed N is a biopharmaceutical company that operates through a partnership-based business model, collaborating with leaders in the healthcare industry and utilizing its proprietary technology platform to develop novel cancer immunotherapies. By leveraging these collaborations and its innovative platform, Affimed N aims to advance the development of effective treatments for cancer.
More about Affimed N v 's Market Share
|
Cadrenal Therapeutics Inc
Share Performance
+82.23%
One Year
|
Cadrenal Therapeutics Inc
Profile
Cadrenal Therapeutics Inc's business model revolves around the development and commercialization of innovative therapies in the field of renal diseases.
More about Cadrenal Therapeutics Inc's Market Share
|
Vaccinex Inc
Share Performance
-20.30%
This Year
|
Vaccinex Inc
Profile
Vaccinex Inc operates on a biopharmaceutical business model, focusing on the development and commercialization of antibody-based therapies. The company utilizes its proprietary ActivMAb? Antibody Discovery Technology to discover and develop novel antibody therapeutics for the treatment of various diseases. Vaccinex collaborates with strategic partners and pharmaceutical companies to advance the clinical development and commercialization of its product candidates.
More about Vaccinex Inc 's Market Share
|
Salarius Pharmaceuticals inc
Share Performance
-54.37%
One Year
|
Salarius Pharmaceuticals inc
Profile
Salarius Pharmaceuticals Inc's business model revolves around the development and commercialization of innovative treatments for rare and aggressive cancers.
More about Salarius Pharmaceuticals inc 's Market Share
|
Panbela Therapeutics Inc
Share Performance
-29.52%
This Quarter
|
Panbela Therapeutics Inc
Profile
Panbela Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative and effective treatments for pancreatic cancer. They aim to leverage their expertise in drug development and strategic partnerships to bring novel therapies to the market and address the unmet medical needs of patients with this devastating disease.
More about Panbela Therapeutics Inc 's Market Share
|
Paxmedica Inc
Share Performance
0.00%
This Quarter
|
Paxmedica Inc
Profile
Paxmedica Inc's business model revolves around providing innovative solutions and technologies in the healthcare sector.
More about Paxmedica Inc 's Market Share
|
Neubase Therapeutics inc
Share Performance
+83.50%
One Year
|
Neubase Therapeutics inc
Profile
Neubase Therapeutics Inc is a biotechnology company focused on developing and commercializing small molecule therapies for genetic diseases. They aim to leverage their proprietary modular antisense oligonucleotide platform to create therapeutics that can specifically target and treat multiple genetic diseases.
More about Neubase Therapeutics inc 's Market Share
|
Phio Pharmaceuticals Corp
Share Performance
+19.21%
This Year
|
Phio Pharmaceuticals Corp
Profile
Phio Pharmaceuticals Corp's business model revolves around developing and commercializing innovative RNA-based therapeutics to treat various diseases and improve patient outcomes.
More about Phio Pharmaceuticals Corp 's Market Share
|
Cns Pharmaceuticals Inc
Share Performance
-4.50%
Over The Past 5 Days
|
Cns Pharmaceuticals Inc
Profile
CNS Pharmaceuticals Inc's business model focuses on developing innovative solutions and treatments for central nervous system diseases.
More about Cns Pharmaceuticals Inc 's Market Share
|
Bolt Biotherapeutics Inc
Share Performance
-61.39%
One Year
|
Bolt Biotherapeutics Inc
Profile
Bolt Biotherapeutics Inc's business model focuses on developing novel immunotherapies for the treatment of cancer.
More about Bolt Biotherapeutics Inc 's Market Share
|
Nextcure Inc
Share Performance
-17.54%
This Quarter
|
Nextcure Inc
Profile
NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.
More about Nextcure Inc 's Market Share
|
Ibio inc
Share Performance
-83.35%
This Quarter
|
Ibio inc
Profile
Ibio Inc is a plant-based biologics company that focuses on the development and manufacturing of therapeutic proteins. They utilize their proprietary plant-based expression system to produce biotherapeutics quickly and cost-effectively. By leveraging their platform, Ibio aims to address unmet medical needs and provide affordable and accessible treatments to patients worldwide.
More about Ibio inc 's Market Share
|
Abvc Biopharma Inc
Share Performance
+158.06%
One Year
|
Abvc Biopharma Inc
Profile
ABVC Biopharma Inc is a pharmaceutical company that focuses on the development and commercialization of innovative biopharmaceutical products.
More about Abvc Biopharma Inc's Market Share
|
I mab
Share Performance
+0.40%
Over The Past 5 Days
|
I mab
Profile
The I Mab business model focuses on the development and commercialization of innovative biopharmaceutical products. They specialize in the research and development of novel antibodies and other therapeutic agents to address unmet medical needs. By collaborating with strategic partners and leveraging their expertise in drug discovery and clinical development, I Mab aims to bring transformative treatments to patients globally.
More about I mab's Market Share
|
Lumos Pharma Inc
Share Performance
-0.69%
30 Days
|
Lumos Pharma Inc
Profile
Lumos Pharma Inc is a biopharmaceutical company that focuses on developing therapeutics for rare diseases. Their business model revolves around identifying and repurposing existing drugs to create innovative treatments for patients with unmet medical needs in the rare disease space.
More about Lumos Pharma Inc 's Market Share
|
Alimera Sciences Inc
Share Performance
+91.03%
This Quarter
|
Alimera Sciences Inc
Profile
Alimera Sciences Inc operates under a business model focused on research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company primarily specializes in creating products for the treatment of retinal diseases, such as diabetic macular edema (DME), utilizing their proprietary sustained-release delivery technology. These products are designed to provide long-term treatment options for patients, offering potential benefits such as less frequent injections and improved patient compliance.
More about Alimera Sciences Inc's Market Share
|
Tempest Therapeutics Inc
Share Performance
-36.54%
This Quarter
|
Tempest Therapeutics Inc
Profile
Tempest Therapeutics Inc is a biotechnology company focused on developing small molecule therapeutics to treat cancer and other diseases. Their business model revolves around identifying novel targets within the immune system and designing drugs that modulate these targets to enhance the body's immune response against cancer cells. Through strategic collaborations and partnerships, they aim to accelerate the development and commercialization of their product candidates.
More about Tempest Therapeutics Inc 's Market Share
|
Werewolf Therapeutics Inc
Share Performance
-58.68%
One Year
|
Werewolf Therapeutics Inc
Profile
Werewolf Therapeutics Inc operates with a business model focused on utilizing innovative technologies to develop therapies targeting cancer using immune cell activation.
More about Werewolf Therapeutics Inc 's Market Share
|
Oncternal Therapeutics Inc
Share Performance
-89.68%
One Year
|
Oncternal Therapeutics Inc
Profile
Oncternal Therapeutics Inc's business model focuses on developing and commercializing novel therapies for the treatment of cancer.
More about Oncternal Therapeutics Inc 's Market Share
|
Y mabs Therapeutics inc
Share Performance
-63.25%
One Year
|
Y mabs Therapeutics inc
Profile
Ymabs Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for the treatment of cancer.
More about Y mabs Therapeutics inc 's Market Share
|
Enliven Therapeutics Inc
Share Performance
-2.78%
Over The Past 5 Days
|
Enliven Therapeutics Inc
Profile
Enliven Therapeutics Inc's business model focuses on developing and providing effective therapeutic solutions that enhance patient wellness and quality of life.
More about Enliven Therapeutics Inc 's Market Share
|
Pliant Therapeutics Inc
Share Performance
-7.25%
Over The Past 5 Days
|
Pliant Therapeutics Inc
Profile
Pliant Therapeutics Inc operates with a business model focused on developing novel therapeutics to address fibrotic diseases. The company conducts extensive research to identify and target specific molecular pathways involved in fibrosis, with the aim of developing effective treatments. Pliant Therapeutics collaborates with academic institutions and conducts preclinical and clinical studies to bring its products to market and improve the lives of patients suffering from fibrotic conditions.
More about Pliant Therapeutics Inc 's Market Share
|
Xoma Royalty Corporation
Share Performance
-7.50%
This Year
|
Xoma Royalty Corporation
Profile
Xoma Corporation operates under a business model focused on the development and commercialization of novel therapeutics. The company primarily concentrates on creating antibody-based therapies to address unmet medical needs. Xoma also engages in collaborations and partnerships with other pharmaceutical companies to advance their product pipeline and expand their reach in the market.
More about Xoma Royalty Corporation's Market Share
|
Protagonist Therapeutics inc
Share Performance
+36.84%
This Year
|
Protagonist Therapeutics inc
Profile
Protagonist Therapeutics Inc's business model focuses on the development and commercialization of novel peptide-based therapeutics.
More about Protagonist Therapeutics inc 's Market Share
|
Chinook Therapeutics Inc
Share Performance
+0.27%
Over The Past 5 Days
|
Chinook Therapeutics Inc
Profile
Chinook Therapeutics is a biotechnology company focused on the development of precision medicines for kidney diseases and other rare disorders. Their business model revolves around identifying and targeting specific pathways involved in the progression of kidney diseases, leveraging innovative technologies and partnerships to develop novel therapies that can improve patient outcomes. By prioritizing the unmet needs in the field of kidney diseases, Chinook aims to deliver transformative treatments to patients while creating value for their stakeholders.
More about Chinook Therapeutics Inc 's Market Share
|
Rhythm Pharmaceuticals inc
Share Performance
+19.12%
This Quarter
|
Rhythm Pharmaceuticals inc
Profile
Rhythm Pharmaceuticals Inc's business model focuses on developing and commercializing therapies for rare genetic disorders that result in unmet medical needs.
More about Rhythm Pharmaceuticals inc 's Market Share
|
Nuvalent Inc
Share Performance
-6.24%
This Year
|
Nuvalent Inc
Profile
Nuvalent Inc's business model entails developing innovative pharmaceutical solutions utilizing its proprietary technology and expertise.
More about Nuvalent Inc 's Market Share
|
Adc Therapeutics Sa
Share Performance
-22.63%
Over The Past 5 Days
|
Adc Therapeutics Sa
Profile
Adc Therapeutics Sa is a biotechnology company that focuses on the development and commercialization of antibody drug conjugates (ADCs) for the treatment of cancer. Their business model revolves around using their proprietary pyrrolobenzodiazepine (PBD) technology to create highly potent ADCs that selectively target cancer cells while minimizing damage to healthy cells. They aim to collaborate with global pharmaceutical companies to co-develop and potentially commercialize their ADC candidates, generating revenue through licensing agreements and milestone payments.
More about Adc Therapeutics Sa's Market Share
|
Adagene Inc
Share Performance
-7.77%
This Year
|
Adagene Inc
Profile
Adagene Inc is a biotechnology company that develops novel antibody therapeutics for cancer treatment by leveraging its proprietary Dynamic Precision Library platform. Their business model involves partnering with pharmaceutical companies for the development and commercialization of their products.
More about Adagene Inc 's Market Share
|
Rafael Holdings Inc
Share Performance
-10.23%
This Year
|
Rafael Holdings Inc
Profile
Rafael Holdings Inc is a diversified holding company that invests in commercial real estate and pharmaceutical research and development. They acquire and lease properties to generate rental income and also develop innovative therapies for the treatment of cancer and other diseases. Their business model combines a focus on long-term real estate investments with investment in life science research and development.
More about Rafael Holdings Inc's Market Share
|
Sources: Syros Pharmaceuticals Inc and all companies mentioned above in this report
|
